Pharmaceutical Information |
Drug Name |
Levocabastine hydrochloride |
Drug ID |
BADD_D01270 |
Description |
Levocabastine is a selective second-generation H1-receptor antagonist used for allergic conjunctivitis. Levocabastine was discovered at Janssen Pharmaceutica in 1979. |
Indications and Usage |
As an ophthalmic for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis. Also used as a nasal spray for allergic rhinitis. |
Marketing Status |
approved; investigational |
ATC Code |
S01GX02; R01AC02 |
DrugBank ID |
DB01106
|
KEGG ID |
D01717
|
MeSH ID |
C047340
|
PubChem ID |
54384
|
TTD Drug ID |
D08SEI
|
NDC Product Code |
65089-0042 |
UNII |
124XMA6YEI
|
Synonyms |
levocabastine | 1-(4-cyano-4-(4-fluorophenyl)cyclohexyl)-3-methyl-4-phenyl-4-piperidinecarboxylic acid | livostin | livocab | levophta | levocabastine hydrochloride | lévophta | Bilina |
|
Chemical Information |
Molecular Formula |
C26H30ClFN2O2 |
CAS Registry Number |
79547-78-7 |
SMILES |
CC1CN(CCC1(C2=CC=CC=C2)C(=O)O)C3CCC(CC3)(C#N)C4=CC=C(C=C4)F.Cl |
Chemical Structure |
|
|
ADRs Induced by Drug |
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|